Mesenchymal stem cells therapy for Ischaemic stroke: Mechanism and progress.
Li S., Huang H., Deng W., Wu Q., Zhao Y., Zhai L.
Clinical Trial on Stroke Research, published in Exp Neurol (2026) — summary generated from the PubMed abstract.
Several human studies show positive signals, while research methods and sample sizes continue to develop.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Clinical Trial
- Journal
- Exp Neurol (2026)
- Country
- United States
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 42035844
- DOI
- 10.1016/j.expneurol.2026.115795
Abstract (original English)
Ischaemic stroke is a leading global cause of death and long-term disability. Current acute interventions, notably thrombolysis and mechanical thrombectomy, are limited by narrow therapeutic windows and primarily focus on vascular recanalization. These approaches often fail to address the sustained neurovascular injury, persistent inflammation, and insufficient endogenous repair that underlie long-term functional impairment. In this context, mesenchymal stem cells (MSCs) have emerged as a highly promising regenerative strategy for ischemic stroke, targeting the multifaceted pathophysiology beyond acute revascularization. Sourced predominantly from bone marrow, umbilical cord, and adipose tissue, MSCs exert effects primarily through their multimodal paracrine actions. They home to the injury site and orchestrate the local immune microenvironment by dampening excessive inflammation and promoting a shift in macrophages toward a pro-repair phenotype. Furthermore, MSCs enhance neurovascular plasticity and tissue regeneration through the release of bioactive factors and extracellular vesicles. This review provides a comprehensive analysis of MSCs sources and their multimodal mechanisms of action, synthesizes preclinical evidence and clinical trial advancements in stroke, discusses persisting translational challenges, and outlines future directions in the field. Collectively, MSCs-bas
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
Evidence level
Several human studies show positive signals, while research methods and sample sizes continue to develop.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.
Related research
- Level AMeta-analysisEurope PMC
Stem cell therapy for ischemic stroke: neuroimaging approaches and evidence from a systematic review
Meta-analysis on Stroke Research, published in Front Neurol (2026) — summary generated from the PubMed abstract.
- 2026
Front Neurol - Level AMeta-analysisEurope PMC
Efficacy and safety of stem cell therapy for myocardial infarction and heart failure: an updated systematic review and meta-analysis of randomized controlled trials
Meta-analysis with a reported sample of 3345 on Cardiovascular Disease, Stroke Research, published in Syst Rev (2026) — summary generated from the PubMed abstract.
- 2026
- n = 3345
Syst Rev - Level AMeta-analysisEurope PMC
Safety and Efficacy of Transendocardial Stem Cells Therapy in Chronic Ischemic Heart Failure: A Systematic Review and Meta-analysis of Randomized Controlled Trials
Meta-analysis on Cardiovascular Disease, Stroke Research, published in Curr Cardiol Rev (2025) — summary generated from the PubMed abstract.
- 2025
Curr Cardiol Rev - Level AMeta-analysisEurope PMC
Efficacy and Potential Mechanisms of Umbilical Cord-Derived Mesenchymal Stem Cells in the Treatment of Ischemic Stroke in Animal Models: A Meta-Analysis
Meta-analysis on Stroke Research, published in CNS Neurosci Ther (2025) — summary generated from the PubMed abstract.
- 2025
CNS Neurosci Ther5 citations - Level AMeta-analysisPubMed
The inconclusive superiority debate of allogeneic versus autologous MSCs in treating patients with HFrEF: a systematic review and meta-analysis of RCTs.
Meta-analysis with a reported sample of 1184 on Cardiovascular Disease, Stroke Research, published in Stem Cell Res Ther (2025) — summary generated from the PubMed abstract.
- 2025
- n = 1184
Stem Cell Res Ther2 citations - Level ASystematic ReviewEurope PMC
In vitro and In vivo Studies on Mesenchymal Stem Cells for Ischemic Stroke Therapy: A Scoping Review of The Therapeutic Effect
Systematic Review on Stroke Research, published in Stem Cells Cloning (2025) — summary generated from the PubMed abstract.
- 2025
Stem Cells Cloning